Q32 Bio (QTTB) Competitors

Q32 Bio (NASDAQ:QTTB) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Do insiders & institutionals believe in QTTB or ZNTL?

31.3% of Q32 Bio shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has stronger valuation and earnings, QTTB or ZNTL?

Q32 Bio has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Q32 Bio is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	N/A	N/A	-$47.73M	-$4.94	-0.46
Zentalis Pharmaceuticals	$26.87M	3.87	-$165.84M	-$3.13	-0.46

Do analysts rate QTTB or ZNTL?

Q32 Bio currently has a consensus price target of $12.17, suggesting a potential upside of 429.91%. Zentalis Pharmaceuticals has a consensus price target of $8.37, suggesting a potential upside of 479.01%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zentalis Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is QTTB or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -65.48% beat Q32 Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	-447.33%	-59.77%
Zentalis Pharmaceuticals	N/A	-65.48%	-51.05%

Which has more risk and volatility, QTTB or ZNTL?

Q32 Bio has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Does the media favor QTTB or ZNTL?

In the previous week, Q32 Bio and Q32 Bio both had 3 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 1.25 beat Q32 Bio's score of 0.63 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zentalis Pharmaceuticals beats Q32 Bio on 10 of the 13 factors compared between the two stocks.